REG - PureTech Health PLC - PRTC Voluntarily Delists Nasdaq Depositary Shares

Puretech HealthAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260429:nRSc2947Ca&default-theme=true

RNS Number : 2947C  PureTech Health PLC  29 April 2026

29 April 2026

PureTech Health plc

 

PureTech Announces Intention to Voluntarily Delist American Depositary Shares
from Nasdaq and Concentrate Trading on the London Stock Exchange

 

PureTech to maintain its primary listing on the London Stock Exchange

Simplification of listing structure expected to enhance operational efficiency
and focus resources on advancing the Company's portfolio

 

PureTech Health plc (https://puretechhealth.com/)  (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company
dedicated to giving life to science and transforming innovation into value,
today announced that it has notified The Nasdaq Stock Market LLC ("Nasdaq") of
its intention to voluntarily delist its American Depositary Shares ("ADSs"),
each representing the right to receive ten (10) ordinary shares of the
Company. Following the effectiveness of the delisting, PureTech's ordinary
shares will remain listed on the London Stock Exchange ("LSE"), which will
continue to serve as the Company's primary trading venue.

 

Following a review of the Company's listing structure and shareholder trading
patterns, the Board of Directors determined that maintaining a dual listing is
no longer necessary. The substantial majority of trading volume, liquidity,
and price discovery for PureTech's shares occurs on the LSE, and the majority
of the Company's current investor base as well as the Company's governance
framework are centered in the United Kingdom.

 

This decision reflects PureTech's ongoing commitment to disciplined capital
allocation, focused execution, and long-term shareholder value creation. The
cost and regulatory and administrative demands of maintaining a dual listing
are significant, and concentrating trading on the London Stock Exchange will
simplify governance, streamline overhead, and align the Company's structure
with its operational and strategic priorities.

 

Following the delisting, and until such time as PureTech may consider
terminating its American Depositary Receipt ("ADR") program, PureTech expects
its ADSs to be quoted and traded on the over-the-counter market via a
sponsored Level 1 ADR program. No action is required to be taken by ADS
holders at this time.

 

Robert Lyne, Chief Executive Officer of PureTech, commented:

"We have determined that concentrating our listing on the London Stock
Exchange is the most effective way to support our shareholders and execute our
strategy. This decision reflects where the meaningful trading volume and
liquidity in our shares has consistently occurred, whilst maintaining access
to both the UK and global investment community. By simplifying our listing
structure, we are streamlining overhead, preserving capital, and ensuring that
our resources are focused on advancing our differentiated portfolio and
delivering long-term value."

 

PureTech expects to file a Form 25 with the U.S. Securities and Exchange
Commission ("SEC") relating to the delisting of its ADSs on or about May 11,
2026. The delisting is expected to become effective ten days thereafter, with
the last day of trading of the Company's ADSs on Nasdaq expected to be on or
about May 20, 2026.

 

Following the delisting, PureTech intends to file a Form 15F with the SEC to
deregister its securities and terminate its reporting obligations under the
Securities Exchange Act of 1934, as amended (the "Exchange Act"). Upon such
filing, the Company's reporting obligations with the SEC will be suspended
immediately.  The termination of the Company's registration and reporting
obligations is expected to become effective no later than 90 days after such
filing if there are no objections from the SEC.

 

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving
life to science and transforming innovation into value. We do this through a
proven, capital-efficient R&D model focused on opportunities with
validated pharmacology and untapped potential to address significant patient
needs. This strategy has produced dozens of therapeutic candidates, including
three that have received U.S. FDA approval. By identifying, shaping, and
de-risking these high-conviction assets, and scaling them through dedicated
structures backed by external capital, we accelerate their path to patients
while creating sustainable value for shareholders.

 

For more information, visit www.puretechhealth.com or connect with us on
LinkedIn (https://www.linkedin.com/company/puretech-health/) and X (formerly
Twitter) @puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to our delisting and deregistration
in the U.S. and related timing, plans for future trading of ADSs, future
prospects, developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual results,
performance and achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other important
factors described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2025, filed with the SEC and in our
other regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
Company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press release.
Except as required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.

 

Contact:

PureTech
Public Relations
publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations
IR@puretechhealth.com (mailto:IR@puretechhealth.com)

UK/EU Media
Ben Atwell, Rob Winder

+44 (0) 20 3727 1000
puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

US Media
Justin Chen
jchen@tenbridgecommunications.com (mailto:jchen@tenbridgecommunications.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUMPCUPQGBR



            Copyright 2019 Regulatory News Service, all rights reserved